Baldwin D S, Gluck M C, Lowenstein J, Gallo G R
Am J Med. 1977 Jan;62(1):12-30. doi: 10.1016/0002-9343(77)90345-x.
An intensive study of the course of lupus nephritis has been undertaken in 88 patients in whom strict morphologic criteria were utilized in classification. All were treated with steroid, and 17 received cytotoxic drugs in addition. Focal proliferative lupus nephritis generally follows a benign course except in the occasional instances when transition to the diffuse proliferative or membranous forms occurs. Membranous lupus nephritis, when characterized by persistent nephrotic syndrome, leads slowly to renal failure, but this progression is aborted in the one-third in whom remission of the nephrotic syndrome can be achieved. A fatal outcome occurs within five years in the majority of those with diffuse proliferative lupus nephritis and the nephrotic syndrome, often in association with necrotizing renal vasculitis, severe hypertension and accelerated renal failure. A small number with the diffuse proliferative form have a remission and then show only mesangial abnormalities, usually, however, with the appearance of glomerular sclerosis. Progressive glomerular sclerosis is observed in some patients and may be a sequel of the remission of the diffuse or focal proliferative lesions, or it may represent still another form of lupus nephritis. Mesangial immune deposits with or without proliferation, at times in the absence of clinical renal disease, are observed early in the course of systemic lupus erythematosus (SLE) and may proceed to the diffuse proliferative or membranous forms. The present observations serve to emphasize the importance of strict morphologic classification in the comparison of different treatment regimens for lupus nephritis. In view of the grave prognosis of established diffuse proliferative lupus nephritis, which probably evolves from a mesangial involvement common to all patients with SLE from its onset, early therapy may be the key to the management of lupus nephritis.
对88例狼疮性肾炎患者进行了深入研究,这些患者在分类时采用了严格的形态学标准。所有患者均接受了类固醇治疗,其中17例还接受了细胞毒性药物治疗。局灶增殖性狼疮性肾炎一般病程良性,除非偶尔转变为弥漫增殖性或膜性形式。膜性狼疮性肾炎,若以持续性肾病综合征为特征,则会缓慢发展至肾衰竭,但在三分之一能够实现肾病综合征缓解的患者中,这种进展会中止。大多数伴有弥漫增殖性狼疮性肾炎和肾病综合征的患者会在五年内出现致命结局,常伴有坏死性肾血管炎、严重高血压和加速性肾衰竭。少数弥漫增殖性形式的患者会缓解,随后仅表现为系膜异常,不过通常会出现肾小球硬化。在一些患者中观察到进行性肾小球硬化,它可能是弥漫性或局灶性增殖性病变缓解后的后遗症,也可能代表狼疮性肾炎的另一种形式。在系统性红斑狼疮(SLE)病程早期即可观察到系膜免疫沉积物,有或无增殖,有时在无临床肾病的情况下也会出现,且可能发展为弥漫增殖性或膜性形式。目前的观察结果强调了在比较狼疮性肾炎不同治疗方案时严格形态学分类的重要性。鉴于已确诊的弥漫增殖性狼疮性肾炎预后严重,它可能从所有SLE患者发病时共有的系膜受累发展而来,早期治疗可能是狼疮性肾炎治疗的关键。